Tenax Therapeutics randomizes 230 patients in pivotal Phase 3 LEVEL study
Tenax Therapeutics (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases, announced a major clinical milestone in its Phase 3 LEVEL trial.


_1357111_640x360_2491407427567-640x360.jpg&w=1200&q=75)


-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)





_1356518_640x360_2491240515795-640x360.jpg&w=1200&q=75)







